CCA
YMAB

Catalyst Capital Advisors’s Y-mAbs Therapeutics YMAB Stock Holding History

Catalyst Capital Advisors’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-400
Closed -$10K – 485
2019
Q1 		$10K Sell
400
-100
-20% -$2.2K ﹤0.01% 305
2018
Q4 		$10K Hold
500
– – ﹤0.01% 306
2018
Q3 		$13K Buy
+500
New +$12.7K ﹤0.01% 318

Other funds holding YMAB

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Catalyst Capital Advisors's YMAB Position: Q2 2019 in Review

Catalyst Capital Advisors sold out of Y-mAbs Therapeutics (YMAB) in Q2 2019, closing a stake of 400 shares — an estimated $10K sold.

Catalyst Capital Advisors first reported a position in YMAB in Q3 2018 and held it in 3 quarters. The position peaked at $13K in Q3 2018. 59 funds tracked by Wall St. Rank hold YMAB as of Q2 2019.

  • Catalyst Capital Advisors reported no remaining Y-mAbs Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Catalyst Capital Advisors sold 400 Y-mAbs Therapeutics shares in Q2 2019, an estimated $10K.
  • Catalyst Capital Advisors first reported a position in Y-mAbs Therapeutics in Q3 2018 and held it in 3 quarters.
  • Catalyst Capital Advisors's Y-mAbs Therapeutics position peaked at $13K in Q3 2018.
  • 59 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q2 2019.

Based on Catalyst Capital Advisors's 13F filing for Q2 2019, filed 8 Aug 2019.